All News

2019

April

Media Release / Apr 15, 2019

Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD

Read More
Media Release / Apr 15, 2019

Europe-Africa partnership spearheads development of next-generation antimalarial drug

Read More
Media Release / Apr 03, 2019

Sandoz resubmits biosimilar pegfilgrastim application to US FDA

Read More
Media Release / Apr 01, 2019

Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre

Read More

March

Media Release / Mar 14, 2019

Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy

Read More

January

People walking in front of a building on the Novartis Campus, Basel in Switzerland.
Featured News / Jan 30, 2019

Novartis 2018 Financial Results

Novartis CEO Vas Narasimhan announced the company’s fourth quarter and 2018 full year results.

Read More
Media Release / Jan 30, 2019

Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

Read More
2018

December

Media Release / Dec 04, 2018

Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data

Read More

November

Media Release / Nov 20, 2018

Novartis rises to second place in 2018 Access to Medicine Index

Read More
Media Release / Nov 02, 2018

Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More